Regulus Therapeutics Company Insiders
| RGLS Stock | USD 1.61 0.03 1.83% |
Regulus Therapeutics employs about 32 people. The company is managed by 10 executives with a total tenure of roughly 5 years, averaging almost 0.0 years of service per executive, having 3.2 employees per reported executive. Breaking down Regulus Therapeutics' management performance can provide insight into the firm performance.
Regulus Therapeutics' Insider Buying Vs Selling
50
Selling | Buying |
Latest Trades
| 2024-07-25 | Kathryn J Collier | Acquired 4000 @ 1.82 | View | ||
| 2024-01-18 | Joseph P Hagan | Disposed 14580 @ 1.19 | View |
Monitoring Regulus Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Regulus |
Regulus Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.4239) % which means that it has lost $0.4239 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7236) %, meaning that it created substantial loss on money invested by shareholders. Regulus Therapeutics' management efficiency ratios could be used to measure how well Regulus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.03 in 2024. Return On Capital Employed is likely to drop to -1.47 in 2024. At this time, Regulus Therapeutics' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 4.4 M in 2024, whereas Other Current Assets are likely to drop slightly above 1.3 M in 2024.Common Stock Shares Outstanding is likely to gain to about 19.9 M in 2024, whereas Net Loss is likely to drop (34.2 M) in 2024.
Regulus Therapeutics Workforce Comparison
Regulus Therapeutics is rated second in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 182. Regulus Therapeutics retains roughly 32.0 in number of employees claiming about 18% of equities under Health Care industry.
Regulus Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regulus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regulus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Regulus Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Regulus Therapeutics Notable Stakeholders
A Regulus Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Regulus Therapeutics often face trade-offs trying to please all of them. Regulus Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Regulus Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Joseph MBA | CEO Director | Profile | |
| MHS MD | Head President | Profile | |
| Christopher JD | General VP | Profile | |
| MS MT | VP Operations | Profile | |
| MS MD | Senior Regulatory | Profile | |
| Crispina CPA | Chief Officer | Profile | |
| Denis Drygin | Chief Officer | Profile | |
| Firuz Shakoori | Head CMC | Profile | |
| Daniel Penksa | Principal Accounting Officer, Controller | Profile | |
| Edmund Lee | Vice Medicine | Profile |
About Regulus Therapeutics Management Performance
The success or failure of an entity such as Regulus Therapeutics often depends on how effective the management is. Regulus Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Regulus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Regulus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.98) | (1.03) | |
| Return On Capital Employed | (1.40) | (1.47) | |
| Return On Assets | (0.98) | (1.03) | |
| Return On Equity | (1.42) | (1.35) |
Please note, the imprecision that can be found in Regulus Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Regulus Therapeutics. Check Regulus Therapeutics' Beneish M Score to see the likelihood of Regulus Therapeutics' management manipulating its earnings.
Regulus Therapeutics Workforce Analysis
Traditionally, organizations such as Regulus Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Regulus Therapeutics within its industry.Regulus Therapeutics Manpower Efficiency
Return on Regulus Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 938.7K | |
| Net Loss Per Executive | 3M | |
| Working Capital Per Employee | 614.7K | |
| Working Capital Per Executive | 2M |
Additional Tools for Regulus Stock Analysis
When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.